According to Peterson's classification, linear morphea is one of five subtypes of localized scleroderma (LS) \[[@cit0001]\]. Unlike systemic sclerosis (SS), linear morphea and other variants of LS are characterized by lack of visceral involvement, Raynaud's phenomenon, sclerodactyly or nailfold capillary changes \[[@cit0002], [@cit0003]\]. Although extracutaneous manifestations can occur in linear morphea, these are different from the visceral involvement seen in SS \[[@cit0004]\]. The face, scalp and extremities are usually affected in linear morphea, which can be accompanied by bone involvement, growth retardation and flexion contractures \[[@cit0004], [@cit0005]\]. From single linear indurated plaques and pigmentary changes, through widespread atrophy of skin and muscles, this form may lead to movement abnormalities and poorly healing ulcers. Dermatomal distribution of the mentioned skin lesions has been observed and available data suggest that sclerotic plaques may be localized along the Blaschko lines \[[@cit0006]\]. Patients may present with elevated titers of one or more autoantibodies, most commonly antinuclear antibodies (ANA). Although no morphea-specific autoantibodies have been reported, anti-single stranded DNA antibodies (anti-ssDNA) and anti-histone antibodies (AHA) are frequently present in linear morphea \[[@cit0007]\]. Rheumatoid factor (RF) and anti-topoisomerase IIα antibody can be elevated, but it occurs more often in other forms of morphea, e.g. generalized morphea \[[@cit0008]\]. Several forms of linear morphea are distinguished, including: linear morphea of the extremities, en coup de sabre, progressive facial hemiatrophy \[[@cit0001]\], and recently described unilateral generalized morphea (UGM).

A 65-year-old male patient with a history of hypertension and type 2 diabetes mellitus presented with extensive plaques of sclerosis, pigmentary lesions, and atrophy of the skin and muscles on the right side of the body. First signs of the disease were observed at the age of 32. There was no known family history of skin disorders and no history of infection, trauma, drug use or toxic exposure. Despite many years of various treatment, skin lesions localized on the right side of the body were progressing continuously.

Physical examination revealed extensive, unilateral, indurated, hypopigmented and hyperpigmented lesions with a loss of adnexal skin structures, resulting in muscle atrophy of the right upper and lower limbs, right half of the face and torso ([Figure 1](#f0001){ref-type="fig"}). The circumferences of the right upper and lower limbs compared with the left side were 9 cm and 15 cm smaller, respectively. This difference was greater by approximately 1--2 cm compared with the previous examination 2 years earlier. Small, not healing ulcerations located on abdominal skin were observed and squamous cell carcinoma in the lesions was excluded by histopathological examination. Noteworthy, no cutaneous abnormalities were observed on the left side of the body. Despite widespread skin lesions and muscle atrophy, no significant internal organ involvement was observed. Chest X-ray and computed tomography revealed degenerative changes of the spine and ribs. Barium esophagography excluded esophageal hernia, gastroesophageal reflux disease and impaired lower esophageal sphincter function. Abdominal ultrasound showed an additional spleen and fatty liver. Histopathological examination confirmed the diagnosis of cutaneous scleroderma.

![Unilateral, indurated plaques with loss of adnexal skin structures, with muscle atrophy of the chest, abdomen, right upper and lower extremities (**A**, **B**), right half of the face and head (**C**, **D**)](PDIA-35-70258-g001){#f0001}

Complete blood count, urinalysis and other routine laboratory tests were normal, except slightly elevated serum transaminases. Autoantibody screening revealed positive ANA with a titer 1 : 640 of the homogenous and cytoplasmic pattern, positive anti-smooth muscle antibodies (ASMA) and liver kidney microsome type 1 antibody (anti-LKM-1)*.* Laboratory tests performed 2 years earlier revealed increased ANA with a titer of 1 : 2560. The diagnostic process for autoimmune liver disease is currently ongoing. RF and *Borrelia burgdorferi* serology were negative. Genetic testing showed karyotype of 45XY,t(13;14)(q10;q10) with Robertsonian translocation between chromosomes 13 and 14, which may explain reproduction failure reported by the patient.

The patient was first diagnosed at the age of 32. According to the clinical and histological features, the diagnosis of *Sclerodermia circumscripta generalisata* was established. He initially presented only with few plaques, but the condition significantly progressed over time and for this reason the patient was closely followed up. Previous therapy, including vitamin PP and E, procaine penicillin, topical and oral corticosteroids and Bath PUVA, was unsuccessful. During subsequent hospitalization, the diagnosis has been modified, and diagnosis of UGM as a rare variant of the linear form of localized scleroderma was established. The patient received treatment with oral methotrexate (MTX) 12.5 mg per week and prednisone 40 mg daily. Despite the introduced therapy, skin lesions progressed and no improvement was observed, thus the patient was started on cyclosporine 3.45 mg/kg daily to prevent further progression of the disease.

In 2002, Nagai *et al.* first reported UGM, an uncommon variant of localized scleroderma. A 6-year-old boy presented with plaques on the right side of the body. Laboratory results revealed ANA with a titer of 1 : 320, elevated concentration of anti-ssDNA and positive RF \[[@cit0009]\]. Up to date, further six cases of UGM in young adults have been described in the literature \[[@cit0010]--[@cit0012]\]. Moreover, a case of unilateral multisegmental morphea, a subtype of UGM, in an infant was also reported \[[@cit0013]\]. Similarly to our patient, physical examination of these subjects revealed unilateral hyperpigmentation, indurated plaques, sclerosis or hypopigmentation with skin thickening, and without cutaneous abnormalities on the opposite side. Furthermore, no internal organs were affected nor sclerodactyly or periungular telangiectasia were observed. Only one patient suffered from Raynaud's phenomenon, which was unilateral, too \[[@cit0010]\]. Laboratory tests revealed positive ANA in all cases, whereas an antibody profile determination was unspecific. Appelhans *et al.* reported positive ASMA in 2 patients, which were not present in the rest of UGM cases \[[@cit0010]\]. In addition to ASMA, in our case we observed the presence of LKM-1, which requires further observation for autoimmune liver disease. According to the literature, the rest of chemical and immunological parameters in described UGM patients remained within the range. Summary of all reported UGM cases is presented in [Table 1](#t0001){ref-type="table"}.

###### 

Summary of all reported unilateral generalized morphea cases

  Authors \[ref.\]                        Onset \[age\]   ANA        Anti-dsDNA   Anti-ssDNA   AHA        ASMA       AM A       *Borrelia*   RF         Additional features
  --------------------------------------- --------------- ---------- ------------ ------------ ---------- ---------- ---------- ------------ ---------- ---------------------------------------------------------------------------------
  Nagai *et al.* \[[@cit0009]\]           5               1 : 320    Unknown      Positive     Unknown    Unknown    Unknown    Unknown      Positive   
  Appelhans *et al*. \[[@cit0010]\]       13              1 : 1250   Negative     Unknown      Positive   Negative   Negative   Negative     Positive   CIC, anti-fibrillarin
  Appelhans *et al.* \[[@cit0010]\]       17              1 : 2560   14 IU/ml     Unknown      Negative   Positive   Negative   Negative     Negative   Unilateral Raynaud's phenomenon
  Appelhans *et al.* \[[@cit0010]\]       8               1 : 2560   82 IU/ml     Unknown      Positive   Negative   Positive   Negative     Positive   Increased level of PIIIP
  Appelhans *et al.* \[[@cit0010]\]       4               1 : 1280   Negative     Unknown      Negative   Positive   Negative   Negative     Negative   
  Gerceker Turk *et al.* \[[@cit0011]\]   25              1 : 320    Negative     Negative     Negative   Negative   Negative   Negative     Negative   Vibration and silica exposure
  Rodriguez *et al.* \[[@cit0012]\]       12              1 : 320    Negative     Negative     Positive   Unknown    Unknown    Negative     Negative   Carpal tunnel syndrome and contractures, mild trauma
  Current case                            32              1 : 640    Negative     Negative     Negative   Positive   Negative   Negative     Negative   Anti-LKM-1, karyotype of 45XY,t(13;14)(q10;q10) with Robertsonian translocation

ANA -- anti-nuclear antibodies, anti-dsDNA -- anti-double-stranded DNA antibodies, anti-ssDNA -- anti-single-stranded DNA antibodies, AHA -- anti-histone antibodies, ASMA -- anti-smooth muscle antibodies, AM A -- anti-mitochondrial antibody, RF -- rheumatic factor, CIC -- circulating immune complexes, PIIIP -- human type III procollagen, anti-LKM-1 -- liver kidney microsome type 1 antibody.

Unilateral generalized morphea comprises of unilateral skin involvement, early onset of symptoms, positive ANA and negative tests for *Borrelia burgdorferi*. Besides these common features, no clear diagnostic pattern has been established so far. UGM usually is classified as a very unique variant of linear morphea. Linear morphea accounts for 20% of LS cases and is the most common form in children and adolescents affecting 64% of young patients with morphea \[[@cit0004]\]. However, the onset of UGM may also occur during adulthood, as seen in our patient. The etiology of the disease remains to be delineated. Immunological factors, *Borrelia burgdorferi* infection and environmental factors, including medications, injections, trauma or radiation therapy have been hypothesized to play a vital role in the pathogenesis of this condition \[[@cit0002]--[@cit0004], [@cit0014]\].

Although no standard therapeutic strategy for UGM exists, different topical and systemic treatment options used in LS have been proposed to be beneficial in UGM. Topical corticosteroids and calcipotriene therapy should be considered in the active phase of the disease \[[@cit0002]\]. This therapy was effective in the first described UGM patient \[[@cit0009]\]. UVA 1 irradiation and PUVA can be used as monotherapy or as a part of combined treatment \[[@cit0010]\]. Recent studies have shown satisfactory efficacy of systemic corticosteroids and MTX in UGM \[[@cit0010]--[@cit0012]\]. Cyclosporine A, mycophenolate mofetil, azathioprine, TNF-α inhibitors and other medications used to treat linear morphea seem to be an alternative to the UGM treatment \[[@cit0003]\]. The existing pharmacological regimens combined with physical and surgical therapy should be an inseparable part of the treatment to avoid development of indivertible damage.
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